Novo Nordisk A S (NONOF) — SEC Filings

Overview

Novo Nordisk A S (NONOF) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 6-K filed on Nov 25, 2025: Novo Nordisk A/S announced on November 25, 2025, positive results from a Phase 2 trial of its drug amycretin for type 2 diabetes. The trial showed statistically significant weight loss of up to 14.5% and HbA1c reductions of up to 89.1% achieving levels below 7% at 36 weeks. The drug appeared to have

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 12 bullish, 1 bearish, 36 neutral, 1 mixed. The dominant filing sentiment for Novo Nordisk A S is neutral.

Filing Type Overview

Novo Nordisk A S (NONOF) has filed 49 6-K, 1 20-F with the SEC between Nov 2024 to Dec 2025.

Filings by Year

2025 · 2024

Recent Filings (50)

• 6-K Filing — 6-K · Dec 23, 2025
• Novo Nordisk's Amycretin Shows Strong Weight Loss in Diabetes Trial — 6-K · Nov 25, 2025 Risk: medium
  Novo Nordisk A/S announced on November 25, 2025, positive results from a Phase 2 trial of its drug amycretin for type 2 diabetes. The trial showed statistically
• Novo Nordisk Alzheimer's Trials Fail to Meet Primary Endpoint — 6-K · Nov 24, 2025 Risk: high
  Novo Nordisk announced on November 24, 2025, that its Phase 3 Evoke and Evoke+ trials for an Alzheimer's disease treatment did not show a statistically signific
• Novo Nordisk Discloses Insider Share Transactions — 6-K · Nov 17, 2025 Risk: low
  On November 17, 2025, Novo Nordisk A/S disclosed transactions in its shares by board members, executives, and associated persons. This disclosure is in accordan
• 6-K Filing — 6-K · Nov 14, 2025
• 6-K Filing — 6-K · Nov 12, 2025
• Novo Nordisk to Lower GLP-1 Prices for US Medicare — 6-K · Nov 7, 2025 Risk: medium
  Novo Nordisk announced on November 6, 2025, an agreement with the U.S. Administration to expand access to its GLP-1 obesity medicines for more Americans at a lo
• 6-K Filing — 6-K · Nov 5, 2025
• Novo Nordisk proposes Metsera acquisition — 6-K · Oct 30, 2025 Risk: medium
  On October 30, 2025, Novo Nordisk A/S submitted an unsolicited proposal to acquire Metsera, Inc. This potential acquisition includes Metsera's early and develop
• Novo Nordisk Calls EGM for Board Elections — 6-K · Oct 21, 2025 Risk: low
  Novo Nordisk A/S announced on October 21, 2025, that its Board of Directors has decided to convene an Extraordinary General Meeting. The purpose of this meeting
• Novo Nordisk to Acquire Akero Therapeutics for MASH Portfolio — 6-K · Oct 9, 2025 Risk: medium
  On October 9, 2025, Novo Nordisk A/S announced its intention to acquire Akero Therapeutics for an undisclosed amount. This acquisition aims to bolster Novo Nord
• Novo Nordisk to cut 9,000 jobs for growth reinvestment — 6-K · Sep 10, 2025 Risk: medium
  Novo Nordisk A/S announced on September 10, 2025, a plan to streamline operations and reinvest for growth, particularly in diabetes and obesity. This transforma
• Novo Nordisk Discloses Insider Trading Activity — 6-K · Aug 19, 2025 Risk: low
  On August 19, 2025, Novo Nordisk A/S filed a Form 6-K to report transactions in its shares by board members, executives, and associated persons. This disclosure
• Novo Nordisk's Wegovy Approved for MASH in US — 6-K · Aug 18, 2025 Risk: low
  On August 15, 2025, Novo Nordisk announced that the US Food and Drug Administration (FDA) approved an additional indication for Wegovy® (semaglutide 2.4 mg). Th
• Novo Nordisk Discloses Insider Share Transactions — 6-K · Aug 14, 2025 Risk: low
  Novo Nordisk A/S announced on August 12, 2025, that it is disclosing transactions in its shares made by board members, executives, and associated persons. This
• Novo Nordisk Discloses Insider Share Transactions — 6-K · Aug 8, 2025 Risk: low
  On August 7, 2025, Novo Nordisk A/S disclosed transactions in its own shares by board members, executives, and associated persons. This disclosure is in accorda
• Novo Nordisk Files Routine 6-K Report — 6-K · Aug 6, 2025 Risk: low
  Novo Nordisk A/S filed a Form 6-K on August 6, 2025, reporting its financial information as of June 30, 2025. The filing is a routine report for foreign private
• Novo Nordisk Responds to TRC Capital Mini-Tender Offer — 6-K · Aug 4, 2025 Risk: medium
  On August 4, 2025, Novo Nordisk A/S announced it has received notice of an unsolicited "mini-tender" offer from TRC Capital Investment Corporation. TRC Capital
• Novo Nordisk Lowers 2025 Outlook Despite Strong H1 Growth — 6-K · Jul 29, 2025 Risk: medium
  Novo Nordisk announced on July 29, 2025, that its sales increased by 18% and operating profit grew in the first six months of 2025. However, the company has low
• Novo Nordisk Advances Amycretin to Phase 3 for Weight Management — 6-K · Jun 13, 2025 Risk: low
  Novo Nordisk announced on June 12, 2025, that it will advance both subcutaneous and oral formulations of amycretin into Phase 3 clinical development for weight
• Novo Nordisk CEO Lars Fruergaard Jørgensen to Step Down — 6-K · May 16, 2025 Risk: medium
  Novo Nordisk announced on May 16, 2025, that CEO Lars Fruergaard Jørgensen will step down as CEO by mutual agreement with the Board. He will continue in his rol
• Novo Nordisk Discloses Insider Share Transactions — 6-K · May 9, 2025 Risk: low
  On May 9, 2025, Novo Nordisk A/S disclosed transactions in its shares by board members, executives, and associated persons. This disclosure is in accordance wit
• Novo Nordisk Files Q1 2025 Report — 6-K · May 7, 2025 Risk: low
  Novo Nordisk A/S filed a Form 6-K on May 7, 2025, reporting its first quarter results for the period ending March 31, 2025. The company, headquartered in Bagsva
• Novo Nordisk Executive VP Camilla Sylvest Departs — 6-K · Apr 3, 2025 Risk: low
  Novo Nordisk A/S announced on April 3, 2025, that Camilla Sylvest will be leaving the company after 28 years, including seven years as executive vice president
• Novo Nordisk Reports Strong 2024 Growth at AGM — 6-K · Mar 31, 2025 Risk: low
  Novo Nordisk A/S held its Annual General Meeting on March 27, 2025, where Helge Lund, chair of the Board of Directors, reported that 2024 was a year of signific
• Novo Nordisk's CagriSema Shows Superior Weight Loss in Phase 3 Trial — 6-K · Mar 10, 2025 Risk: low
  Novo Nordisk announced positive headline results from its Phase 3 REDEFINE 2 trial on March 10, 2025. The trial investigated the efficacy and safety of once-wee
• Novo Nordisk Annual General Meeting Set for March 27 — 6-K · Feb 27, 2025 Risk: low
  Novo Nordisk A/S announced its Annual General Meeting will be held on March 27, 2024, at 2:00 PM CET at Bella Center. The meeting will be partially electronic,
• Novo Nordisk Discloses Insider Trading Activity — 6-K · Feb 7, 2025 Risk: low
  On February 7, 2025, Novo Nordisk A/S filed a Form 6-K to report transactions in its shares by board members, executives, and associated persons. This disclosur
• Novo Nordisk Discloses Insider Share Transactions — 6-K · Feb 6, 2025 Risk: low
  On February 6, 2025, Novo Nordisk A/S disclosed transactions in its own shares by board members, executives, and associated persons. This disclosure is made in
• Novo Nordisk Files 2024 Annual Report — 20-F · Feb 5, 2025 Risk: medium
  Novo Nordisk A/S filed its 20-F annual report for the fiscal year ending December 31, 2024. The filing provides comprehensive financial and operational details
• Novo Nordisk Initiates Share Repurchase Program — 6-K · Feb 4, 2025 Risk: low
  Novo Nordisk A/S announced on February 4, 2025, that it initiated a share repurchase program on November 11, 2024. This program is being conducted in accordance
• Novo Nordisk Initiates Share Repurchase Program — 6-K · Jan 27, 2025 Risk: low
  Novo Nordisk A/S announced on January 27, 2025, that it initiated a share repurchase program on November 11, 2024. This program is being conducted in accordance
• Novo Nordisk Obesity Drug Amycretin Shows Promise in Trial — 6-K · Jan 24, 2025 Risk: medium
  Novo Nordisk A/S announced positive topline results on January 24, 2025, from a Phase 1b/2a clinical trial for its subcutaneous amycretin drug. Amycretin is des
• Novo Nordisk Completes Share Repurchase Program — 6-K · Jan 21, 2025 Risk: low
  Novo Nordisk A/S announced on January 20, 2025, that it has completed a share repurchase program initiated on November 11, 2024. The company repurchased a total
• Novo Nordisk Semaglutide Shows Strong Weight Loss in Obesity Trial — 6-K · Jan 17, 2025 Risk: low
  Novo Nordisk announced headline results from its Phase 3b STEP UP trial on January 17, 2025. The trial investigated subcutaneous semaglutide 7.2 mg for obesity
• Novo Nordisk Completes DKK 1B Share Repurchase — 6-K · Jan 15, 2025 Risk: low
  Novo Nordisk A/S announced on January 13, 2025, that it has completed its share repurchase program initiated on November 11, 2024. The company repurchased a tot
• Novo Nordisk's CagriSema Shows Superior Weight Loss in Obesity Trial — 6-K · Dec 20, 2024 Risk: low
  Novo Nordisk announced positive headline results from its Phase 3 REDEFINE 1 trial on December 20, 2024. The trial investigated CagriSema, a fixed-dose combinat
• Novo Nordisk Completes Acquisition of 3 Manufacturing Sites — 6-K · Dec 18, 2024 Risk: low
  Novo Nordisk announced on December 18, 2024, the completion of its acquisition of three manufacturing sites from Novo Holdings A/S. This acquisition is a conseq
• Novo Nordisk Catalent Acquisition Cleared to Close — 6-K · Dec 16, 2024 Risk: low
  Novo Nordisk A/S announced on December 14, 2024, that the acquisition of Catalent, Inc. by Novo Holdings A/S has received all necessary regulatory approvals. As
• EMA backs Ozempic label update for kidney risk reduction — 6-K · Dec 13, 2024 Risk: low
  On December 12, 2024, Novo Nordisk announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive
• Novo Nordisk Initiates Share Repurchase Program — 6-K · Dec 9, 2024 Risk: low
  On December 9, 2024, Novo Nordisk A/S announced the initiation of a share repurchase program. This program is being conducted in accordance with European regula
• EU Approves Novo Holdings' Catalent Acquisition — 6-K · Dec 6, 2024 Risk: low
  On December 6, 2024, the European Commission approved Novo Holdings A/S' acquisition of Catalent, Inc. This approval is a key step for Novo Nordisk's subsequent
• Novo Nordisk Initiates Share Repurchase Program — 6-K · Dec 2, 2024 Risk: low
  Novo Nordisk A/S announced on December 2, 2024, that it initiated a share repurchase program on November 11, 2024. This program is being conducted in accordance
• Novo Nordisk Launches Share Repurchase Program — 6-K · Nov 25, 2024 Risk: low
  Novo Nordisk A/S announced on November 25, 2024, that it initiated a share repurchase program on November 11, 2024. This program is being conducted in accordanc
• Novo Nordisk Reports Insider Share Transactions — 6-K · Nov 19, 2024 Risk: low
  Novo Nordisk A/S filed a Form 6-K on November 19, 2024, to report transactions in its shares by board members, executives, and associated persons. This disclosu
• Novo Nordisk Initiates Share Repurchase Program — 6-K · Nov 18, 2024 Risk: low
  Novo Nordisk A/S announced on November 18, 2024, that it initiated a share repurchase program on November 11, 2024. This program is being conducted in accordanc
• Novo Nordisk Discloses Insider Share Transactions — 6-K · Nov 14, 2024 Risk: low
  On November 13, 2024, Novo Nordisk A/S disclosed transactions in its shares by board members, executives, and associated persons. This disclosure is in accordan
• Novo Nordisk Discloses Insider Share Transactions — 6-K · Nov 13, 2024 Risk: low
  Novo Nordisk A/S filed a Form 6-K on November 13, 2024, reporting transactions in its shares by board members, executives, and associated persons. This disclosu
• Novo Nordisk Discloses Insider Trading Activity — 6-K · Nov 8, 2024 Risk: low
  On November 8, 2024, Novo Nordisk A/S disclosed transactions in its shares by board members, executives, and associated persons. This disclosure is made in acco
• Novo Nordisk Discloses Insider Share Transactions — 6-K · Nov 7, 2024 Risk: low
  On November 7, 2024, Novo Nordisk A/S disclosed transactions in its shares by board members, executives, and associated persons. This report, filed under Form 6

Related Companies

NVO · CTLT

Frequently Asked Questions